强化血糖控制对新诊断儿童1型糖尿病胰腺β细胞功能影响的随机临床试验
这项在美国6个中心开展的随机双盲临床试验纳入113例新诊断1型糖尿病7至17岁患者,比较强化糖尿病管理(自动胰岛素输注系统,n=61)与标准治疗(持续葡萄糖监测,n=52)对52周时混合餐耐量试验刺激的C肽曲线下面积的影响。结果显示两组C肽下降无显著差异(治疗组间差异-0.01 pmol/mL,95%CI -0.11至0.10,P=0.89),强化管理组目标血糖范围内时间达78% vs 标准治疗组64%(校正差异16%,95%CI 10%至22%)。
要点
- 强化管理组52周C肽曲线下面积从0.57降至0.45 pmol/mL,标准治疗组从0.60降至0.50 pmol/mL,组间差异无统计学显著(P=0.89)。
- 52周时目标血糖范围70至180 mg/dL内时间强化管理组78% vs 标准治疗组64%(校正差异16%,95%CI 10%至22%)。
- 每组各发生1例严重低血糖事件和1例糖尿病酮症酸中毒事件。
核心结论
- 在新诊断1型糖尿病青少年中,包含自动胰岛素输注系统的强化糖尿病管理实现了优异的血糖控制,但未影响52周时胰腺C肽分泌的下降。
研究设计与样本
- 随机双盲临床试验,在美国6个中心开展,随机化时间为2020年7月20日至2021年10月13日,随访于2022年9月15日完成,纳入新诊断1型糖尿病7至17岁青少年。
- 参与者随机分配至强化糖尿病管理(包括使用自动胰岛素输注系统,n=61)或标准治疗(包括使用持续葡萄糖监测,n=52),作为析因设计的一部分,体重30 kg及以上的参与者还被分配接受口服维拉帕米或安慰剂。
- 共113例参与者(平均[SD]年龄11.8[2.8]岁;49例女性[43%];从诊断到随机化的平均[SD]时间24[5]天),108例(96%)完成试验。
主要发现
- 主要结局为诊断后52周时混合餐耐量试验刺激的C肽曲线下面积(胰腺β细胞功能指标)。
- 强化管理组平均C肽曲线下面积从基线0.57 pmol/mL降至52周0.45 pmol/mL,标准治疗组从0.60降至0.50 pmol/mL(治疗组间差异-0.01[95%CI,-0.11至0.10];P=0.89)。
- 52周时通过持续葡萄糖监测测定的目标范围70至180 mg/dL内平均时间强化管理组为78%,标准治疗组为64%(校正差异16%[95%CI,10%至22%])。
- 每组各发生1例严重低血糖事件和1例糖尿病酮症酸中毒事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Near normalization of glucose levels instituted immediately after diagnosis of type 1 diabetes has been postulated to preserve pancreatic beta cell function by reducing glucotoxicity. Previous studies have been hampered by an inability to achieve tight glycemic goals. OBJECTIVE: To determine the effectiveness of intensive diabetes management to achieve near normalization of glucose levels on preservation of pancreatic beta cell function in youth with newly diagnosed type 1 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This randomized, double-blind, clinical trial was conducted at 6 centers in the US (randomizations from July 20, 2020, to October 13, 2021; follow-up completed September 15, 2022) and included youths with newly diagnosed type 1 diabetes aged 7 to 17 years. INTERVENTIONS: Random assignment to intensive diabetes management, which included use of an automated insulin delivery system (n = 61), or standard care, which included use of a continuous glucose monitor (n = 52), as part of a factorial design in which participants weighing 30 kg or more also were assigned to receive either oral verapamil or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was mixed-meal tolerance test-stimulated C-peptide area under the curve (a measure of pancreatic beta cell function) 52 weeks from diagnosis. RESULTS: Among 113 participants (mean [SD] age, 11.8 [2.8] years; 49 females [43%]; mean [SD] time from diagnosis to randomization, 24 [5] days), 108 (96%) completed the trial. The mean C-peptide area under the curve decreased from 0.57 pmol/mL at baseline to 0.45 pmol/mL at 52 weeks in the intensive management group, and from 0.60 to 0.50 pmol/mL in the standard care group (treatment group difference, -0.01 [95% CI, -0.11 to 0.10]; P = .89). The mean time in the target range of 70 to 180 mg/dL, measured with continuous glucose monitoring, at 52 weeks was 78% in the intensive management group vs 64% in the standard care group (adjusted difference, 16% [95% CI, 10% to 22%]). One severe hypoglycemia event and 1 diabetic ketoacidosis event occurred in each group. CONCLUSIONS AND RELEVANCE: In youths with newly diagnosed type 1 diabetes, intensive diabetes management, which included automated insulin delivery, achieved excellent glucose control but did not affect the decline in pancreatic C-peptide secretion at 52 weeks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04233034.
引用
- McVean J, Forlenza GP, Beck RW, et al. Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 36826834. doi:10.1001/jama.2023.2063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。